文献速递艾滋病与性传播感染

HIV感染者换用多替拉韦加拉米夫定48周体成分变化:DOLAM随机试验子分析

48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

换药方案和年龄与48周体重变化独立相关,但DXA测定的体脂、瘦体重和骨密度变化组间无差异。

要点

  • 换药方案和年龄与48周体重变化独立相关。
  • DXA测定的体脂、瘦体重和骨密度变化两组间无显著差异。

核心结论

  • DOLAM试验中换用多替拉韦加拉米夫定48周体重增加,而继续三药方案未增加,但DXA未检测到体脂、瘦体重或骨密度变化的组间差异。

主要发现

  • 换用多替拉韦加拉米夫定和年龄与48周体重变化独立相关(线性回归模型校正基线体重)。
  • DXA测定的体脂变化两组均<0.5%,瘦体重变化两组均<7%,骨密度变化两组均<0.5%,组间无差异。

关键数值与推荐

  • DXA体成分变化采用年龄和性别校正的线性或对数线性混合效应回归模型评估。

临床怎么用

  • HIV感染者换用多替拉韦加拉米夫定后应关注体重变化,尤其年龄较大者。
  • DXA未显示体脂、瘦体重或骨密度的显著组间差异,短期体成分安全性需进一步评估。

局限性

  • 子分析仅纳入68%的DOLAM试验参与者,样本量有限。
  • 随访至48周,长期体成分变化未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Switching to dolutegravir plus lamivudine has been associated with weight gain. We aimed to assess factors associated with weight gain and changes in body composition in people with HIV switching to dolutegravir plus lamivudine in the DOLAM trial (EudraCT 201500027435). METHODS: People with HIV on suppressive triple therapy were randomized to switch to dolutegravir plus lamivudine or to continue triple therapy. Weight and height were measured, and dual X-ray absorptiometry (DXA) scans were performed at baseline and 48 weeks. Factors associated with 48 week weight change were estimated using linear regression models adjusted for weight at baseline. DXA-derived changes were assessed using age- and sex-adjusted linear or log-linear mixed-effects regression models. RESULTS: One hundred and eighty (68% of the DOLAM trial participants) (dolutegravir plus lamivudine, n = 88; triple therapy, n = 92) participants contributed with paired baseline and 48 week DXA scans. Mean (95% CI) weight changes were 1. 362 kg (0.437-2.287) in the dolutegravir plus lamivudine arm and 0.199 kg (-0.742 to 1.140) in the triple therapy arm. Treatment with dolutegravir plus lamivudine and age were independently associated with greater weight change at 48 weeks. DXA-derived changes in body fat mass (<0.5% in both arms), lean mass (<7% in both arms) and bone mineral density scans (<0.5% in both arms) did not differ between arms. CONCLUSIONS: Although weight at 48 weeks increased with dolutegravir plus lamivudine but not with triple therapy in the DOLAM study, we did not detect any significant DXA-derived changes in body fat, lean mass or bone mineral density between arms.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. de Lazzari E, Di Gregorio S, Rojas J, et al. 48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2025. PMID: 40556520. doi:10.1093/jac/dkaf192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。